#USA #Los Angeles #Cancer Research #Aignostics #PanCAN

Aignostics and PanCAN Partnership: A New Era in Pancreatic Cancer Research

In a significant move to advance pancreatic cancer research, Aignostics has teamed up with the Pancreatic Cancer Action Network (PanCAN) for a groundbreaking partnership focused on utilizing artificial intelligence in analyzing extensive multimodal datasets. This collaboration seeks to harness Aignostics’ advanced technology to enhance the existing tools available for researchers tackling one of the toughest forms of cancer.

The collaboration will leverage Aignostics’ AI-driven application, Atlas HE-TME, to analyze pathology images from PanCAN’s SPARK data platform. The goal is to integrate comprehensive spatial profiling into one of the most thorough pancreatic cancer datasets ever created, providing researchers with access to over 4,500 quantitative readouts per image. This impressive data pool will be readily accessible to academic researchers, free of charge, while commercial life sciences entities can obtain licenses for commercial use.

Pancreatic cancer, notorious for its harsh and immunosuppressive characteristics, has presented enormous challenges in treatment efficacy over the years. Although some improvement in patient outcomes has been observed, advancements have been limited, making ongoing research essential. By pairing the analytical power of Atlas HE-TME with the multifaceted SPARK dataset, the partnership aims to unlock novel insights into the underlying biology of pancreatic tumors, thereby paving the way for improved therapeutic strategies.

Viktor Matyas, CEO of Aignostics, expressed pride in contributing to this effort, stating, "PanCAN has built something genuinely rare in SPARK, and we're proud to play a part in making it even more powerful for researchers. Our mission is to transform complex pathology data into actionable insights for patients, and this partnership exemplifies that commitment."

Dr. Sudheer Doss, Chief Business Officer at PanCAN, echoed Matyas’ sentiments, highlighting the collaboration’s potential: "This partnership provides crucial AI resources to enhance the SPARK dataset. By integrating spatial data, we’re creating a better understanding of tumor development and interactions within their environments, which are vital for transformative discoveries."

Aignostics positions itself as an innovator in the field of artificial intelligence, focused on translating complex pathology data into impactful clinical insights. Founded in 2020 as a spin-off from Charité Berlin, the company aims to support personalized medicine through collaboration with biopharma partners, enhancing drug discovery, translational research, clinical trials, and companion diagnostics.

This partnership is particularly timely given the dire need for breakthroughs in treating pancreatic cancer. PanCAN, as a leader in this sector, continues to unite the community around the shared mission of developing advanced treatments and early detection strategies aimed at improving patient outcomes.

For researchers and institutions eager to access the wealth of information in the SPARK dataset, application processes are straightforward. More details can be obtained by visiting PanCAN’s dedicated page for data access requests.

In summary, the collaboration between Aignostics and PanCAN signifies hope in an ongoing fight against pancreatic cancer, combining innovative technology with a robust dataset to enhance research and ultimately improve patient survival rates. As both organizations continue to advocate for progress in pancreatic cancer care, their partnership exemplifies the potential of harnessing advanced technology for life-saving discoveries.

For more information about Aignostics, visit www.aignostics.com and for the Pancreatic Cancer Action Network, please visit their official website.